ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission

Thoracic Cancer
Markus BlaukovitschMichael Studnicka

Abstract

In this case report we describe a 30 year-old Caucasian woman with a histopathological diagnosis of pulmonary adenocarcinoma in both lungs with lipidic and micropapillary growth pattern and ROS1 (C-ros oncogene 1, receptor tyrosine kinase) rearrangement. There is evidence that crizotinib can be used for molecular target therapy in these patients. We enrolled the patient in an off-label program for the treatment of ROS1 rearranged adenocarcinomas with the EML4/anaplastic lymphoma kinase inhibitor crizotinib. After a follow-up of eight weeks we saw a complete remission in both lungs without any signs of metabolic tumor activity. This report shows the importance of testing young patients with adenocarcinomas of the lung for rare oncogenic driver mutations, such as ROS1, with possible molecular treatment options.

References

Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·C BirchmeierM Wigler
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott J RodigLucian R Chirieac
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Jan 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristin BergethonA John Iafrate
May 24, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroyuki YasudaDaniel B Costa
Aug 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takefumi KomiyaGiuseppe Giaccone
Apr 6, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M BosJ Wolf

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Related Papers

Tuberculosis and Respiratory Diseases
Chang-Min Choi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Jennifer M BolandEunhee S Yi
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Min Hwan KimByoung Chul Cho
© 2022 Meta ULC. All rights reserved